, Volume 35, Issue 4, pp 1419–1428 | Cite as

Elevated Plasma Platelet Activating Factor, Platelet Activating Factor Acetylhydrolase Levels and Risk of Coronary Heart Disease or Blood Stasis Syndrome of Coronary Heart Disease in Chinese: A Case Control Study

A Case–Control Study
  • Guo-Hua Zheng
  • Shang-Quan Xiong
  • Li-Juan Mei
  • Hai-Ying Chen
  • Ting Wang
  • Jian-Feng Chu


The purpose of the study was to explore the association between plasma platelet activating factor (PAF) and platelet activating factor acetylhydrolase (PAF-AH) levels and risk of coronary heart disease (CHD) or blood stasis syndrome (BSS) of CHD. Questionnaire, routine clinical assays and plasma levels of PAF, PAF-AH and inflammatory factors hs-CRP and IL-6 were investigated or measured for 120 controls and 150 CHD patients (66 non-BSS and 84 BSS). Plasma PAF levels were higher in CHD patients [49.7 (34.8–73.2 pg/mL)] than in controls [23.8 (14.9–42.3 pg/mL)] (P < 0.001), and in BSS [56.0 (40.1–86.1 pg/mL)] than in non-BSS [47.4 (29.0–67.4 pg/mL)] (P = 0.027). Similarly, plasma PAF-AH levels were higher in CHD patients [11.5 (7.5–15.6 μmol/L)] than in controls [8.1 (5.4–12.6 μmol/L)] (P < 0.001), and in BSS [13.4 (8.7–18.5 μmol/L)] than in non-BSS [9.5 (7.3–14.3 μmol/L)] (P = 0.014). After adjustment for the confounded effects of inflammatory factors or conventional risk factors, plasma PAF and PAF-AH levels still had a significant difference between CHD patients and controls, but plasma PAF-AH rather than PAF levels had a significant difference between BSS and non-BSS. Elevated plasma PAF level contributed to the risk of CHD rather than BSS, and elevated plasma PAF-AH level was an independent risk factor of CHD and BSS.


platelet activating factor platelet activating factor acetylhydrolase coronary heart disease blood stasis syndrome risk factor 



Activated partial thromboplastin time


Body mass index


Blood stasis syndrome


Coronary heart disease

95 % CI

95 % confidence interval




Enzyme-linked immunosorbent assay


High density lipoprotein cholesterol


High sensitivity C-reaction protein


Interleukin 6


Low density lipoprotein cholesterol


Lipoprotein-associated phospholipase A2


Odds ratio


Platelet activating factor


Platelet activating factor acetylhydrolase


Prothrombin time


Standard deviation


Total cholesterol


Traditional Chinese medicine





This study was supported by research funds from the National Natural Science Foundation of China (grant No: 81072726, National Natural Science Foundation of China, Beijing, China) and the Natural Science Foundation of Fujian province (grant No. 2009J01163, Fujian Provincial Department of Science and Technology, Fujian, China).


  1. 1.
    Ross, R. 1999. Atherosclerosis: an inflammatory disease. The New England Journal of Medicine 340(2): 115–126.PubMedCrossRefGoogle Scholar
  2. 2.
    Blake, G.J., and P.M. Rider. 2002. Inflammatory bio-markers and cardiovascular risk prediction. Journal of Internal Medicine 252: 283–294.PubMedCrossRefGoogle Scholar
  3. 3.
    Welch, E.J., R.P. Nalkawadi, Z. Li, P. Lin, S. Ishii, et al. 2009. Opposing effects of platelet-activating factor and lyso-platelet activating factor on neutrophil and platelet activation. Molecular Pharmacology 75: 227–234.PubMedCrossRefGoogle Scholar
  4. 4.
    Uhlig, S., R. Goggel, and S. Engel. 2005. Mechanisms of platelet-activating factor (PAF)-mediated responses in the lung. Pharmacological Reports 57(suppl): 206–221.PubMedGoogle Scholar
  5. 5.
    Vadas, P., M. Gold, B. Perelman, and G.M. Liss. 2008. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. The New England Journal of Medicine 358: 28–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Xu, W., S.H. Xia, H. Wang, H. Chen, and Y.L. Wang. 2007. Role of platelet activating factor in pathogenesis of acute respiratory distress syndrome. Chinese Medical Journal 120: 1840–1844.PubMedGoogle Scholar
  7. 7.
    Karasawa, K. 2006. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochimica et Biophysica Acta 1761: 1359–1372.PubMedCrossRefGoogle Scholar
  8. 8.
    Zalewski, A., and C. Macphee. 2005. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 923–931.PubMedCrossRefGoogle Scholar
  9. 9.
    Ai, M., and M. Madjid. 2009. Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiology 5: 159–173.CrossRefGoogle Scholar
  10. 10.
    Morgan, E.N., E.M. Boyle, W. Yun, and J.C. Kovacich. 1999. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 100(19suppl): ll365–368.Google Scholar
  11. 11.
    Chris, J., D.S. Packard, S.J. Denis, and M.D. Reily. 2000. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. The New England Journal of Medicine 343: 1148–1155.CrossRefGoogle Scholar
  12. 12.
    Magjid, M., M. Ali, and J.T. Willerson. 2010. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Texas Heart Institute Journal 37: 25–39.Google Scholar
  13. 13.
    Karbina, S.A., and E. Ninio. 2006. Plasma PAF-acetylhydrolase: an unfulfilled promise? Biochimica et Biophysica Acta 1761: 1351–1358.CrossRefGoogle Scholar
  14. 14.
    Howard, K.M., M. Abdel, M. Ditmyer, and N. Pate. 2011. Lipopolysaccharide and platelet-activating factor stimulate expression of platelet activating factor acetylhydrolase via distinct signaling pathways. Inflammation Research 60: 735–744.PubMedCrossRefGoogle Scholar
  15. 15.
    Chen, K.J., M. Xue, and H. Yin. 2008. The relationship between platelet activation and coronary heart disease and blood-stasis syndrome. Journal of Capital Medical University 29: 266–269.Google Scholar
  16. 16.
    Ren, J.X., J.X. Liu, C.R. Lin, et al. 2010. Comparative analysis on the biological basis of blood stasis syndrome induced by qi-stagnation and qi-deficiency in patients with unstable angina pectoris. Chinese Journal of Integrated Traditional and Western Medicine. 30: 352–356.PubMedGoogle Scholar
  17. 17.
    Pen, W.J., Z.H. Xing, X. Liao, and W.P. Liu. 2011. Effect of Yiqi Huoxue therapy on serum IL-6, ICAM-1 and TNF-α in patients with stable angina pectoris in qi deficiency and blood stasis. Journal of Traditional Chinese Medicine University of Hunan. 31: 49–51.Google Scholar
  18. 18.
    Zhao, H.Y., W.H. Wang, W.Q. Chen, et al. 2011. Effect of Shanzha Xiaozhi capsule on homocysteine and hypersensitivity-C reactive protein in patients of non-acute coronary heart disease with phlegm and blood stasis syndrome. Journal of New Chinese Medicine 43: 9–11.Google Scholar
  19. 19.
    Ma, X.J., H.J. Yin, and K.J. Chen. 2007. Research progress of correlation between blood stasis syndrome and inflammation. CJITWM 27: 669–672.Google Scholar
  20. 20.
    Chignard, M., J.P. Le Couedic, M. Tence, B.B. Vargaftig, and J. Benveniste. 1979. The role of platelet-activating factor in platelet aggregation [J]. Nature 279: 799–800.PubMedCrossRefGoogle Scholar
  21. 21.
    International Society of Cardiology. 1981. Naming and diagnostic criteria of ischaemic heart disease. Chinese Journal of Cardiology 9: 75–76.Google Scholar
  22. 22.
    Disease Special Committee, Chinese Association of the Integrative Medicine. Standard of syndrome differentiation on coronary heart disease of Chinese medicine. Chinese Journal of Integrated Traditional and Western Medicine (Chin), 1991; 11:257.Google Scholar
  23. 23.
    Hanahan, D.J. 1986. Platelet activating factor: a biologically active phosphoglyceride. Annual Review of Biochemistry 55: 483–509.PubMedCrossRefGoogle Scholar
  24. 24.
    Penna, C., E. Bassino, and G. Alloatti. 2011. Platelet activating factor: the good and bad in the ischemic/reperfused heart. Experimental Biology and Medicine 236: 390–401.PubMedCrossRefGoogle Scholar
  25. 25.
    Montrucchio, G., G. Alloatti, and G. Camussi. 2000. Role of platelet-activating factor in cardiovascular pathophysiology. Physiological Reviews 80: 1669–1699.PubMedGoogle Scholar
  26. 26.
    Gilli, U.O., M.K. Schneider, P. Loetscher, et al. 2005. Human polymorphonuclear neutrophils are recruited by porcine chemokines acting on CXC chemokine receptor 2, and platelet-activating factor. Transplantation 79: 1324–1331.PubMedCrossRefGoogle Scholar
  27. 27.
    Subbanagounder, G., N. Leitinger, T. Peggy, and K.F. Shih. 1999. Evidence that phospholipids oxidation products and/or platelet activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by WEB 2086. Circulation Research 85: 311–318.PubMedCrossRefGoogle Scholar
  28. 28.
    Feng, W., T. Wu, Q.F. Sun, P.S. Yang, and X.L. Liu. 2010. Detection of platelet activating factor in unstimulated mixed saliva and gingival crevicular fluid of periodontitis patients with coronary heart disease. Shanghai Kou Qiang Yi Xue 19: 228–231.PubMedGoogle Scholar
  29. 29.
    Chen, H., P. Zheng, J. Zhu, and L. Zhao. 2010. Platelet-activating factor levels of serum and gingival crevicular fluid in nonsmoking patients with periodontitis and/or coronary heart disease. Clinical Oral Investigations 14: 629–636.PubMedCrossRefGoogle Scholar
  30. 30.
    Garber, A.M., and A.L. Avins. 1994. Triglyceride concentration and coronary heart disease. BMJ 309: 1440–1442.PubMedCrossRefGoogle Scholar
  31. 31.
    Oppenheimaer, G.M. 2006. Profiling risk: the emergence of coronary heart disease epidemiology in the United States. International Journal of Epidemiology 35: 720–730.CrossRefGoogle Scholar
  32. 32.
    Weber, C., and H. Noels. 2011. Atherosclerosis: current pathogenesis and therapeutic option. Nature Medicine 17: 1410–1422.PubMedCrossRefGoogle Scholar
  33. 33.
    Xue, M., K.J. Chen, and H.J. Yin. 2008. Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood stasis syndrome. Chinese Journal of Integrative Medicine 14: 267–273.PubMedCrossRefGoogle Scholar
  34. 34.
    Tsantila, N., A.B. Tsoupras, E. Fragopoulou, and S. Antonopolou. 2011. In vitro and in vivo effects of stains on platelet-activating factor and its metalism. Angiology 62: 209–218.PubMedCrossRefGoogle Scholar
  35. 35.
    Snyder, F. 1989. Biochemistry of PAF: a unique class of biologically active phospholipids. Proceedings of the Society for Experimental Biology and Medicine 190: 125–135.PubMedGoogle Scholar
  36. 36.
    Maseri, A. 1997. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. The New England Journal of Medicine 336: 1014–1016.PubMedCrossRefGoogle Scholar
  37. 37.
    Chen, Y.Z. 2006. The changed concentration of serum IL-6, IL-10 and CHD. Chinese Journal of Microecology. 18: 222–223.Google Scholar
  38. 38.
    Ren, N., T. Huang, J. Shu, J.B. Du, et al. 2007. Changes and prognostic value of serum high sensitivity C reactive protein and interleukin 6 levels in patients with acute coronary syndrome. Acta Academiae Medicinae CPAPF. 16: 497–501.Google Scholar
  39. 39.
    Pasceri, V., J.T. Willerson, and E.T. Yeh. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165–2168.PubMedCrossRefGoogle Scholar
  40. 40.
    Zheng, F., D. Qu, H. Xu, et al. 2009. Relationship between Chinese medicine syndrome and serum level of high-sensitivity C-reactive protein in patients with stable coronary heart disease. CJJIWM 29: 485–489.Google Scholar
  41. 41.
    Arai, H. 2002. Platelet-activating factor acetylhydrolase. Prostaglandins & Other Lipid Mediators 68–69: 83–94.CrossRefGoogle Scholar
  42. 42.
    Macphee, C.H., K.E. Moores, H.F. Boyd, D. Dhanak, et al. 1999. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochemical Journal 338: 479–487.PubMedCrossRefGoogle Scholar
  43. 43.
    Tjoelker, L.W., and D.M. Stafforini. 2000. Platelet-activating factor acetylhydrolases in health and disease. Biochimica et Biophysica Acta 1488: 102–123.PubMedCrossRefGoogle Scholar
  44. 44.
    Itabe, H. 1998. Oxidized phospholipids as a new landmark in atherosclerosis. Progress in Lipid Research 37: 181–207.PubMedCrossRefGoogle Scholar
  45. 45.
    Carlquist, J.F., J.B. Muhlestein, and J.L. Anderson. 2007. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Review of Molecular Diagnostics 7: 511–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Caslake, M.J., C.J. Packard, K.E. Sucking, S.D. Holmes, et al. 2000. Lipoprotein-associated phospholipase A2 platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150: 413–419.PubMedCrossRefGoogle Scholar
  47. 47.
    Samsamshariat, S., G. Basati, A. Movahedian, M. Pourfarzam, and N. Sarrafzadegan. 2011. Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease. Journal of Research in Medical Sciences 16: 674–679.PubMedGoogle Scholar
  48. 48.
    Persson, M., J.A. Nilsson, J.J. Nelson, B. Hedblad, and G. Berglund. 2007. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 190: 388–396.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Guo-Hua Zheng
    • 1
  • Shang-Quan Xiong
    • 2
  • Li-Juan Mei
    • 1
  • Hai-Ying Chen
    • 1
  • Ting Wang
    • 2
  • Jian-Feng Chu
    • 1
  1. 1.Academy of Integrative MedicineFujian University of Traditional Chinese MedicineFuzhouChina
  2. 2.Department of Cardiologic MedicineThe People’s Hospital of Fujian ProvinceFuzhouChina

Personalised recommendations